



THE
BLADDER CANCER
COMPANY

Photocure ASA – CFO transition

Oslo, Norway, 30 June 2026: Photocure ASA (OSE: PHO) is today announcing that Chief Financial Officer Erik Dahl will retire after nearly 14 years of dedicated service to the company. To ensure a seamless transition, Erik will remain with Photocure through the end of December 2026.

Erik's tenure has been instrumental in shaping Photocure's financial strength and growth. "Erik has been a tremendous asset to our team, and we are deeply grateful for everything he has contributed to the company and our shareholders over the years," said Chief Executive Officer Dan Schneider. "He has guided our financial organization through many significant milestones and helped build the strong foundation we stand on today. We wish him the very best and are very grateful for his service."

With ample time to ensure continuity, the search for Erik's successor is already underway. CEO Dan Schneider will serve as acting CFO, with the full support of Photocure's experienced finance team, until the new CFO is appointed.

For more information, please contact:

Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com

Priyam Shah
Vice President Investor Relations
Tel : +17176815072
Email: priyam.shah@photocure.com

About Photocure ASA

Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com/news

This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act and Euronext Oslo Rule Book II - Issuer Rules.